MDxHealth (FRA:O6C1) Total Liabilities: €156.62 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O6C1 MDxHealth SA FRA:O6C1
49 GF Score
Price €0.07
GF Value €0.36
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MDxHealth Total Liabilities?

MDxHealth FRA:O6C1 +9.23% 49 Total Liabilities is €156.62 Mil as of Mar. 2026. GuruFocus rates FRA:O6C1 with a GF Score™ of 49/100 and a GF Value™ of €0.36 (Possible Value Trap). The stock has 5 warning signs investors should review.

MDxHealth's Total Liabilities for the quarter that ended in Mar. 2026 was €156.62 Mil.

MDxHealth's quarterly Total Liabilities declined from Sep. 2025 (€138.49 Mil) to Dec. 2025 (€136.68 Mil) but then increased from Dec. 2025 (€136.68 Mil) to Mar. 2026 (€156.62 Mil).

MDxHealth's annual Total Liabilities increased from Dec. 2023 (€111.80 Mil) to Dec. 2024 (€136.08 Mil) and increased from Dec. 2024 (€136.08 Mil) to Dec. 2025 (€136.68 Mil).

MDxHealth Total Liabilities Historical Data

* Premium members only.

The historical data trend for MDxHealth's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MDxHealth Total Liabilities Chart

MDxHealth Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.93 103.67 111.80 136.08 136.68

MDxHealth Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 156.20 122.69 138.49 136.68 156.62
FRA:O6C1
49GF Score
MDxHealth SA FRA:O6C1
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MDxHealth Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

MDxHealth's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=42.302+(72.339+22.039
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=136.68

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=126.352--10.328
=136.68

MDxHealth's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=35.964+(90.079+30.574
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=156.62

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=139.119--17.498
=156.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €156.62 Mil mean?
MDxHealth (FRA:O6C1) has a Total Liabilities of €156.62 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for MDxHealth and its competitors.
Is MDxHealth's Total Liabilities too high?
MDxHealth's current Total Liabilities is €156.62 Mil. Overall, MDxHealth has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's Total Liabilities compare to AWHL and BIOQ?
MDxHealth's Total Liabilities of €156.62 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for MDxHealth and its competitors. MDxHealth's current Total Liabilities is €156.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
Based on GuruFocus' analysis, MDxHealth (FRA:O6C1) is currently considered Possible Value Trap. The stock's GF Value™ is €0.36, compared to a current price of €0.07 — trading 80.3% below its estimated fair value. The current Total Liabilities is €156.62 Mil. MDxHealth's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For MDxHealth (FRA:O6C1), the current Total Liabilities is €156.62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MDxHealth (FRA:O6C1) Overvalued in 2026?

Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued. The current stock price of €0.07 is trading 80.3% below its estimated GF Value™ of €0.36. GuruFocus considers MDxHealth to be Possible Value Trap.

Key valuation signals for FRA:O6C1:

  • Total Liabilities: €156.62 Mil
  • GF Value™: €0.36 vs. price of €0.07 (80.3% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the FRA:O6C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MDxHealth Business Description

Other Exchanges MDXH:USA
Address Zone Industrielle des Hauts-Sarts, Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
49GF Score

Get the complete analysis for FRA:O6C1

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.36
GF Value